Barinthus Biotherapeutics plc. Income Statement
BRNS|5 years of annual SEC 10-K data (FY2021-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
Barinthus Biotherapeutics plc. reported $0 in revenue and $66M in net loss for FY2025. Revenue has declined at a 45.0% compound annual rate over the past 3 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $802.0K | $44.7M | $268.0K | $4.8M |
| SG&A Expense | $40.8M | $39.8M | $6.4M | $25.1M | $10.5M |
| R&D Expense | $25.6M | $44.9M | $42.4M | $20.4M | $14.4M |
| Operating Income | -$70.6M | -$83.9M | -$4.0M | -$45.2M | -$20.0M |
| Interest Expense | - | - | $19.0K | $2.7M | $3.6M |
| Income Tax | -$175.0K | -$3.1M | -$4.5M | -$28.0K | $95.0K |
| Net Income | -$66.4M | -$73.3M | $5.3M | -$50.9M | -$17.7M |
| EPS (Basic) | -$1.55 | -$1.91 | $0.14 | -$1.96 | -$2.24 |
| EPS (Diluted) | -$1.55 | -$1.91 | $0.14 | -$1.96 | -$2.24 |
| Shares Outstanding | 40.2M | 38.6M | 37.7M | 37.2M | 8.0M |
| Operating Margin | - | -10463.1% | -9.0% | -16873.5% | -415.8% |
| Profit Margin | - | -9145.5% | 11.9% | -18979.5% | -367.3% |